Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients

The coronavirus disease 2019 (COVID-19) may cause cytokine storm and respiratory illness such as pneumonia and progressive respiratory failure. Tocilizumab (TCZ), a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, was approved as an alternative treatment for severe COVID-19 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yong, Chen, Yongfeng, Zhou, Xiangdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924788/
https://www.ncbi.nlm.nih.gov/pubmed/35308307
http://dx.doi.org/10.1155/2022/6375870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924788/
https://www.ncbi.nlm.nih.gov/pubmed/35308307
http://dx.doi.org/10.1155/2022/6375870

Ejemplares similares